focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Share News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 12th Mar 2014 09:03

Ashtead Group: Citi raises target price from 850p to 1075p keeping a buy recommendation.Barratt Developments: Goldman Sachs reduces target price from 527p to 502p and downgrades to neutral.British Land: Jefferies downgrades to hold with a target price of 707p.Brooks Macdonald Group: Canaccord Genuity increases target price from 1620p to 1780p, but downgrades from buy to hold.Brown (N) Group: UBS lowers target price from 565p to 535p and downgrades from neutral to sell.Cape: Canaccord Genuity ups target price from 300p to 360p maintaining a buy recommendation.Close Brothers Group: Berenberg raises target price from 1330p to 1640p and maintains a buy recommendation. JP Morgan increases target price from 1357p to 1480p and stays with its overweight rating. UBS raises target price from 1340p to 1420p maintaining a neutral rating.Countrywide: Goldman Sachs ups target price from 748p to 764p, while downgrading to neutral.Craneware: Investec raises target price from 615p to 645p keeping a buy recommendation.Crest Nicholson Holdings: Goldman Sachs shifts target price from 525p to 530p and upgrades to strong buy.esure Group: Deutsche Bank moves target price from 300p to 313p and keeps a buy recommendation. Citi shifts target price from 291p to 294p retaining a buy recommendation. Canaccord Genuity lowers target price from 305p to 295p maintaining its buy recommendation.Fenner: Jefferies lowers target price from 505p to 490p, while staying with its buy recommendation. Espirito Santo cuts target price from 410p to 400p and retains its neutral rating. UBS cuts target price from 500p to 480p leaving its buy recommendation unaltered.Go-Ahead Group: Deutsche Bank increases target price from 1640p to 2100p, while downgrading to hold. RBC Capital raises target price from 1800p to 2300p keeping its neutral rating.Hangar8: Westhouse Securities takes target price from 270p to 310p, but downgrades to add.Hikma Pharmaceuticals: Panmure Gordon ups target price from 1375p to 1400p, while downgrading from buy to hold.Hummingbird Resources: Cantor Fitzgerald moves target price from 68p to 80p leaving its buy recommendation unchanged.Hunting: Investec ups target price from 830p to 890p, but downgrades from buy to hold.IFG Group: N+1 Singer upgrades to buy with a target price of 150p.IMI: RBC Capital cuts target price from 1600p to 1550p and retains an outperform rating. Espirito Santo raises target price from 1530p to 1650p and upgrades to buy.Inchcape: Deutsche Bank ups target price from 655p to 685p and reiterates its hold recommendation. Nomura takes target price from 580p to 600p and maintains its neutral rating.Inmarsat: Jefferies moves target price from 790p to 800p and retains a buy recommendation.International Consolidated Airlines Group: Liberum Capital takes target price from 450p to 550p and keeps a buy recommendation.Kazakhmys: UBS raises target price from 210p to 300p and maintains a neutral rating.Land Securities: Jefferies downgrades to hold with a target price of 1112p.Merlin Entertainment: JP Morgan moves target price from 415p to 430p and maintains an overweight rating.Modern Water: Numis cuts target price from 77p to 62p, while its buy recommendation remains unchanged.Morgan Advanced Materials: Espirito Santo raises target price from 280p to 320p and retains a neutral rating.Persimmon: Goldman Sachs cuts target price from 1892p to 1840p and downgrades from strong buy to buy.Phoenix IT: Panmure Gordon lowers target price from 144p to 136p, while upgrading from hold to buy.Plethora Solutions: Daniel Stewart moves shifts target price from 18.9p to 25.6p and keeps a buy recommendation.Premier Farnell: UBS lowers target price from 240p to 235p and stays with its neutral rating.Redrow: Goldman Sachs raises target price from 341p to 423p upgrading to buy.Rentokil Initial: Credit Suisse ups target price from 95p to 125p and keeps a neutral rating.Rightmove: Goldman Sachs reduces target price from 4360p to 3607p and downgrades from strong buy to buy.Rockhopper Exploration: Canaccord Genuity reduces target price from 345p to 265p, but stays with its buy recommendation.Rotork: Espirito Santo increases target price from 2500p to 2600p and stays with its neutral rating.Servelec Group: Investec raises target price from 284p to 310p and maintains its buy recommendation.Spirax-Sarco Engineering: Espirito Santo raises target price from 3000p to 3200p and reiterates a neutral rating.Travis Perkins: Berenberg cuts target price from 1880p to 1800p and retains a hold recommendation.Tyman: Numis raises target price from 285p to 320p reiterating an add rating.WEIR Group: Espirito Santo raises target price from 2600p to 2800p and maintains a buy recommendation.
More News
19 Nov 2013 08:07

AIM IN BRIEF: Centamin Further Reduces Stake In Nyota Minerals

Read more
30 Sep 2013 13:34

Plethora Cuts Losses As It Focuses Entirely Premature Ejaculation Treatment

Read more
23 Sep 2013 12:12

UK WINNERS & LOSERS: Ariana Resources Stands Out From Weak Gold Miners

Read more
20 Sep 2013 13:06

MARKET COMMENT: UK Trades Flat Prior To US Open; Nyota, Plethora Lead AIM

Read more
20 Sep 2013 12:43

Plethora Solutions Premature Ejaculation Spray Gets Positive Opinion

Read more
20 Sep 2013 12:26

UPDATE 1-New Roche breast cancer drug wins backing in Europe and Japan

* Kadcyla approved in Japan, recommended for approval in EU * EU agency also backs Algeta/Bayer prostate cancer drug LONDON, Sept 20 (Reuters) - Roche's new breast cancer drug Kadcyla was approved in Japan on Friday and recommended for approval in Europe, building on February's U.S. g

Read more
12 Apr 2013 11:50

Plethora Solutions Chairman resigns

Plethora Solutions Holdings Chairman Bill Robinson is stepping down from his role at the pharmaceuticals company. Jim Mellon will take over as Chairman with immediate effect temporarily until a successor is found. Robinson, who has been Chairman since 2009, will remain a Non-Executive Director of

Read more
18 Mar 2013 14:25

Plethora Solutions secures much needed financing

Plethora Solutions has secured 2.1m pounds in funding after its subsidiary The Urology Co. fell into administration. The funds were raised through the placing of 106.2m new ordinary shares at a price of 2.0p per share, representing an 8.0% interest. It comes after the company announced it was in

Read more
14 Feb 2013 08:24

Plethora Solutions shares jump following new equity update

Shares in pharmaceuticals company Plethora Solutions jumped sharply on Thursday after the group reported that it was in 'advanced discussions' with an investor to provide new equity financing to the group. The group, whose share price had recently been declining, added that support was also being s

Read more
5 Feb 2013 11:07

Plethora Solutions shares plunge on urgent financing talks

Plethora Solutions is in urgent discussions with third parties to finance the company's working capital purposes. Shares in the pharmaceutical company plummeted 55.00% to 2.25p at 11:18 following Tuesday's announcement. The company said it remained focused on the development of SD502, a drug for

Read more
17 Oct 2012 15:15

Plethora's PSD502 drug has mass market potential

Plethora Solutions is definitely a small cap stock to watch and in an exclusive interview with Sharecast, Daniel Stewart analyst Vadim Alexandre has reiterated the bull case for the biotech tiddler. Plethora Solutions has a drug, PSD502, aimed at treating premature ejaculation, which has passed two

Read more
15 Mar 2012 12:06

Small caps round-up: HMV, Corero, ANGLE ...

HMV Group, the struggling entertainment media seller, has confirmed that it is still pondering what to do with its live music business. HMV added that a number of parties have indicated an interest in acquiring the business. There has been press speculation recently about who might be interested in

Read more
14 Mar 2011 17:36

Plethora's testosterone boost

AIM-quoted sexual health products developer and distributor Plethora Solutions has added the pan-European rights for testosterone replacement treatment Striant SR to the UK rights it already has. Plethora has secured the rights from Columbia Laboratories and it will sell the product through its di

Read more
7 Sep 2010 13:48

Small caps round-up: Charlemagne, Highams, Hydro...

Hedge fund manager Charlemagne's assets under management rise have picked up in the past two months to stand at $3.04bn at end August. The modest recovery follows a fall in the first half to $2.8bn, blamed on declining markets. Operating profits were $1.2m, down from $1.3m, with one-off performanc

Read more
19 Jul 2010 07:25

Plethora Solutions Launches New Product, hi-Argenol >PLE.LN

LONDON (Dow Jones)--Plethora Solutions Holdings PLC (PLE.LN), a U.K.-based specialty pharmaceutical company, said Monday it has launched a new product, hi-Argenol, for the maintenance and improvement of male sexual health. -Shares closed Friday at 11.75 pence valuing the company at GBP5.21 milli

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.